<a href="https://www.fiercebiotech.com/medtech/nuvalent-teams-guardant-health-companion-diagnostics" hreflang="en">Nuvalent teams up with Guardant Health for companion diagnostics</a>
Nuvalent has partnered with Guardant Health to develop companion diagnostics for its targeted cancer therapies, utilizing Guardant's "Infinity" platform for tissue and liquid biopsy tests. This collaboration aims to enhance patient identification for clinical trials and support regulatory approvals for Nuvalent's investigational drugs, including a new ALK-selective tyrosine kinase inhibitor for advanced non-small cell lung cancer.
Nuvalent's collaboration with Guardant Health to develop companion diagnostics for targeted cancer drugs highlights the critical role precision diagnostics play in oncology drug development. This partnership leverages Guardant’s liquid biopsy technology to enhance patient identification for clinical trials and supports potential regulatory approvals, which could improve trial efficiency and expedite market entry for Nuvalent's investigational therapies. This trend underscores the increasing importance of integrating biomarker-driven strategies in drug development to ensure successful commercialization and regulatory success.